Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

OUTLOOK THERAPEUTICS, INC.

(OTLK)
  Report
Delayed Quote. Delayed Nasdaq - 12/07 04:00:01 pm
1.49 USD   +8.76%
12:42pCORPORATE PRESENTATION : December 2021
PU
12/03NORTH AMERICAN MORNING BRIEFING : Oil Rises, Stock -3-
DJ
12/02INSIDER BUY : Outlook Therapeutics
MT
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
12/01/2021 12/02/2021 12/03/2021 12/06/2021 12/07/2021 Date
1.29(c) 1.38(c) 1.33(c) 1.37(c) 1.49 Last
2 025 129 3 209 434 2 661 674 1 383 866 1 687 180 Volume
-14.57% +6.98% -3.62% +3.01% +8.76% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 - - -
Net income 2021 -45,9 M - -
Net Debt 2021 - - -
P/E ratio 2021 -5,32x
Yield 2021 -
Sales 2022 2,33 M - -
Net income 2022 -52,9 M - -
Net Debt 2022 - - -
P/E ratio 2022 -5,32x
Yield 2022 -
Capitalization 334 M 334 M -
Capi. / Sales 2021 -
Capi. / Sales 2022 143x
Nbr of Employees 8
Free-Float 53,7%
More Financials
Company
Outlook Therapeutics, Inc. is a late clinical-stage biopharmaceutical company. The Company is engaged in developing ophthalmic formulation of bevacizumab for use in retinal indications. bevacizumab is a full-length, humanized anti-VEGF (Vascular Endothelial Growth Factor) recombinant monoclonal antibody (mAb), that inhibits VEGF and associated angiogenic activity. The Company is developing a product candidate namely... 
More about the company
Ratings of Outlook Therapeutics, Inc.
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
-
More Ratings
All news about OUTLOOK THERAPEUTICS, INC.
12:42pCORPORATE PRESENTATION : December 2021
PU
12/03NORTH AMERICAN MORNING BRIEFING : Oil Rises, Stock -3-
DJ
12/02INSIDER BUY : Outlook Therapeutics
MT
11/30Outlook Therapeutics Announces Closing of $57.5 Million Bought Deal, Including Full Exe..
AQ
11/29OUTLOOK THERAPEUTICS : Announces $10 Million Bought Deal Offering of Common Stock - Form 8..
PU
11/29OUTLOOK THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Unregistered Sale..
AQ
11/29Outlook Therapeutics Announces Closing of $57.5 Million Bought Deal, Including Full Exe..
AQ
11/24Outlook Therapeutics Upsizes Bought-Deal Offering of Common Shares to $50 Million
MT
11/23Outlook Therapeutics Increases Previously Announced Bought Deal Offering of Common Stoc..
AQ
11/23Outlook Therapeutics Unveils $10 Million Common Stock Offering; Shares Sink
MT
11/23Outlook Therapeutics Announces $10 Million Bought Deal Offering of Common Stock
GL
11/16OUTLOOK THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Creation of a Dir..
AQ
11/16CORPORATE PRESENTATION : November 2021
PU
11/16Outlook Therapeutics, Inc. announced that it expects to receive $10 million in funding ..
CI
11/15Outlook Therapeutics Presents NORSE TWO Phase 3 Pivotal Safety and Efficacy Data for ON..
AQ
More news
News in other languages on OUTLOOK THERAPEUTICS, INC.
12/02ACHATS D'INITIÉS : Outlook Therapeutics
11/24Outlook Therapeutics porte à 50 millions de dollars son offre d'actions ordinaires dans..
11/23Outlook Therapeutics propose une offre d'actions ordinaires d'un montant de 10 millions..
10/12Outlook Therapeutics déclare que le bevacizumab ophtalmique présente des données d'inno..
09/28L'essai clinique d'Outlook Therapeutics sur les maladies oculaires confirme un profil d..
More news
Chart OUTLOOK THERAPEUTICS, INC.
Duration : Period :
Outlook Therapeutics, Inc. Technical Analysis Chart | OTLK | US69012T2069 | MarketScreener
Technical analysis trends OUTLOOK THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 1,49 $
Average target price 7,00 $
Spread / Average Target 370%
EPS Revisions
Managers and Directors
C. Russell Trenary President, Chief Executive Officer & Director
Lawrence A. Kenyon CFO, Secretary, Treasurer & Director
Ralph H. Thurman Independent Executive Chairman
Jennifer M. Kissner Senior Vice President-Clinical Development
Terry Dagnon Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
OUTLOOK THERAPEUTICS, INC.-0.77%307
MODERNA, INC.153.98%107 578
LONZA GROUP AG25.98%56 683
IQVIA HOLDINGS INC.46.84%50 262
SEAGEN INC.-16.63%26 699
CELLTRION, INC.-43.31%23 888